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ABSTRACT
Umbilical cord blood plasma (UCB-PL) contains various cytokines, growth factors, 
and immune modulatory factors that regulate the proliferation and function of immune 
cells and adult stem cells. Despite its therapeutic potential, the effects of UCB-PL 
treatment in conditions of ischemic brain injury have yet to be investigated. In this 
study, we demonstrated that both behavioral and structural impairments resulting 
from ischemic brain injury were significantly prevented/reversed after intravenous 
administration of UCB-PL relative to the vehicle control. As early as 1-week post-
ischemia, an increased number of newborn cells in the subventricular zone and a 
reduced number of activated microglial cells in the peri-infarct area were observed 
in the UCB-PL group, suggesting that enhanced neurogenesis and/or the suppression 
of inflammation may have contributed to functional protection/recovery. Moreover, 
UCB-PL was more effective than plasma derived from a 65-year-old healthy adult 
for the treatment of ischemia-related structural and functional deficits, indicating 
that UCB-PL had greater therapeutic potential. This study provides valuable insights 
into the development of a safe, effective, and cell-free strategy for the treatment of 
ischemic brain damage and a much-needed alternative for patients who are ineligible 
for thrombolytic therapy.
INTRODUCTION
Stroke, a devastating cerebrovascular disease, 
is classified into ischemic and hemorrhagic subtypes 
based on its etiology [1, 2]. More than three-quarters 
of all cases are reported to result from ischemic injury. 
Thrombolytic therapy is the first line therapy for ischemic 
stroke. However, the window of effectiveness of tissue 
plasminogen activator (tPA) treatment is only 4.5 h post-
ischemic injury, which allows only 8% of stroke patients 
to receive tPA therapy [3, 4]. New cell-based therapeutic 
strategies are in development that use bone marrow- or 
adipose tissue-derived mesenchymal stem cells (MSCs) 
and neural stem cells. However, in the case of stem cell 
administration to patients, the potential risk of serious side 
effects such as uncontrolled growth of the transplanted 
cells [5] and clogging of small blood vessels by occasional 
unexpected cell aggregates cannot be avoided. Therefore, 
from a clinical safety perspective, cell-free therapeutic 
strategies are more desirable if comparable efficacy can 
be achieved. Although conditioned media of MSCs were 
previously tested as cell-free therapeutic strategies [6, 7], 
the exposure to fetal bovine serum during the initial 
establishment and expansion of the MSCs raised concerns 
of xenopathogen transmission.
Umbilical cord blood contains a large number 
of stem cells (i.e., MSCs and hematopoietic stem 
cells). Human umbilical cord blood plasma (UCB-PL) 
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contains a variety of cytokines, growth factors, and 
immune modulatory factors that affect the proliferation 
and function of immune cells and MSCs [8–11]. Given 
the beneficial constituents of UCB-PL, it may have 
therapeutic utility for the treatment of a variety of disease 
states. Furthermore, no risk of xenopathogen transmission 
is associated with therapies that use UCB-PL.
In this study, we demonstrate that UCB-PL 
administration exerted therapeutic effects on both 
structural and behavioral recovery in a rat model of focal 
ischemic stroke. The results of this study provide valuable 
insights into the development of a safe, alternative, and 
cell-free therapeutic strategy for stroke patients who are 
ineligible for thrombolytic therapy.
RESULTS
UCB-PL administration promotes behavioral 
recovery in a rat model of acute ischemic stroke
The experimental design is illustrated in Figure 1. 
Behavioral performances were examined between the 
control (PBS-treated) and UCB-PL groups, which had 
received treatment every 2 days starting from the third 
day after MCAO surgery for a total of 9 treatments 
(Figure 2A). Behavioral assessments were performed on 
days 3, 7, 14, and 21 post-MCAO surgery, and animals 
were euthanized after the last behavioral test on day 21 for 
histological analysis (Figure 2A). 
No significant differences in body weight were 
observed between the control group and the UCB-PL group 
(Figure 2B). The UCB-PL group displayed significant 
improvements in the corner turn test compared with the 
control group from the first week after MCAO surgery; 
this functional difference became statistically significant 
from the second week after MCAO surgery (Figure 2C). 
The UCB-PL group also showed significant differences in 
neurological recovery as indicated by the mNSS as early 
as 1 week after MCAO surgery (Figure 2D). Lastly, the 
UCB-PL group showed better performance in the foot 
fault test compared with the control group (Figure 2E). 
Taken together, these behavioral analyses suggest that 
intravenous UCB-PL attenuated or reversed behavioral 
impairments after MCAO. 
UCB-PL administration reduces brain tissue 
damage after MCAO
Because behavioral improvements were evident 
following UCB-PL administration, we examined whether 
UCB-PL also limited the extent of or enhanced recovery 
from MCAO-mediated brain damage. MCAO-associated 
brain damage was measured using in vivo MRI prior to 
euthanasia. The UCB-PL group displayed a significant 
reduction in brain tissue damage compared to the control 
(PBS) group (8.3% in the UCB-PL group [n = 6] vs. 
34.2% in the control group [n = 6], p < 0.05) (Figure 3A). 
Histological analysis after sacrificing the rats also 
showed significant brain tissue recovery in the UCB-PL 
Figure 1: The experimental study design.
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group compared to the control group. The reduced brain 
volumes were 47% and 36% of the hemisphere in the 
control and UBC-PL groups, respectively (n = 6, p < 0.05) 
(Figure 3B).
This result suggested that UCB-PL treatment was 
effective for the prevention or reversal of brain damage 
resulting from ischemic injury, which is consistent with 
our behavioral observations. 
UCB-PL administration enhances neural stem 
cell proliferation in the subventricular zone after 
MCAO
To explore the mechanism underlying the functional 
and structural recovery elicited by UCB-PL treatment, we 
first examined whether UCB-PL administration increased 
the proliferation of otherwise quiescent neural stem cells 
in the subventricular zone (SVZ). Rats were injected 
with BrdU for 5 consecutive days starting 1 day after 
MCAO surgery and were euthanized 1 day after the last 
BrdU injection (Figure 4A). The number of BrdU+ cells 
in the SVZ of the infarcted hemisphere was significantly 
greater in the UCB-PL group than in the control group 
(1.36-fold, n = 5, p < 0.01) (Figure 4B, 4C). Our results 
demonstrated that UCB-PL administration during the 
acute stage of stroke enhanced the proliferation of neural 
stem cells in the SVZ, suggesting that this effect at least in 
part accounted for the observed behavioral and structural 
recovery after ischemic brain injury. 
UCB-PL administration decreases microglial 
activation after MCAO
It has been suggested that limiting the extent 
of microglial activation after injury promotes neural 
proliferation and reduces post-ischemic brain damage 
Figure 2: Functional recovery after UCB-PL administration in an acute ischemic stroke model. UCB-PL was intravenously 
administered during the acute phase of a rat model of stroke, and effects on behavioral performance were measured. (A) The schedule of 
the experiment. (B) The physiological status and health of the rats in each group were measured using body weight. (C–E) Behavioral 
performances of rats in each group were measured using the corner turn test (C), the modified neurologic severity score (mNSS) (D), and 
the foot fault test (E). n = 7 for the control group (blue line), and n = 9 for the UCB-PL group (red line). **p < 0.01, *p < 0.05; data are 
presented as the mean ± SEM. 
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[12–14]. When rat brain slices were immunostained for 
both Iba1, a general marker for microglia, and ED1, a 
marker specific for activated microglia, an approximately 
50% reduction in ED1+ area was observed near the peri-
infarct striatum in the UCB-PL group relative to the 
control group (0.5-fold, n = 4, p < 0.05) (Figure 5A, 5B). 
However, we also observed a slight reduction in Iba1+ 
area near the peri-infarct striatum in the UCB-PL group 
relative to the control group (Figure 5C). These results 
indicated that UCB-PL administration significantly 
decreased microglial activation near the peri-infarct 
striatum.
UCB-PL is more effective than aged-PL for the 
treatment of ischemic injury 
A previous study of mouse parabiosis suggested 
that systemic administration of young mouse plasma 
elicited greater improvements in cognitive function 
than aged mouse plasma [15]. Based on this result, 
we speculated that UCB-PL would offer greater 
benefits than aged-PL after MCAO in rats. To test this 
hypothesis, we administered (via the tail vein) either 
UCB-PL or plasma from a 65-year-old healthy subject 
(aged-PL) 5 times post-MCAO on days 0, 3, 7, 14, and 
Figure 3: UCB-PL administration reduced brain tissue damage caused by MCAO injury. (A) (Left panel) In vivo brain 
MRI was performed prior to euthanasia to measure the size of the damaged brain area. (Right panel) The percentage of the damaged area 
in the ipsilateral hemisphere was compared between the control and UCB-PL groups. Eight sections per rat were analyzed to quantify the 
percentage of the remaining intact ipsilateral area. (B) (Left panel) Cresyl violet staining of the rat brains was performed to measure the size 
of the damaged brain area. (Right panel) The graph indicates the percentages of the hemispheres that were damaged by ischemia in each 
group. n = 6/group, *p < 0.05, **p < 0.01.
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Figure 5: Reduced microglial activation after UCB-PL administration. (A) The expression levels of Iba1 and ED1 in the 
striatum were compared between the control and UCB-PL groups. (B) The percentage of ED1-positive area per high-power field was 
measured. (C) The percentage of Iba1-positive area per high-power field was measured. n = 4/group, *p < 0.05, scale bar: 10 µm.
Figure 4: Increased neural stem cell proliferation in the subventricular zone (SVZ) after UCB-PL administration. 
(A) The schedule of the experiment; BrdU, 5-bromo-2-deoxyuridine. (B) The expression levels of GFAP and BrdU in the SVZ were 
compared between the control and UCB-PL groups. (C) The number of BrdU-positive cells per high-power field was counted. n = 5/group, 
**p < 0.01, scale bar: 10 µm. 
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21, and performed both behavioral and histological 
analyses (Figure 6A).
With respect to the mNSS, the UCB-PL group 
displayed better recovery than both the aged-PL and 
control groups. The difference was statistically significant 
at 1 week after MCAO surgery (Figure 6B, left). In the 
beam balance test, which is a sensitive motor assay, the 
UCB-PL group showed more significant improvements 
in behavioral performance than the aged-PL or control 
groups from 1 week post-MCAO and thereafter 
(Figure 6B, right).
Nissl staining of brain sections harvested at 3 
weeks post-MCAO demonstrated that the UCB-PL group 
displayed a lesser degree of brain damage than the aged-
PL group (24.0% in the UCB-PL group  [n = 7] vs. 63.0% 
in the aged-PL group [n = 7], p < 0.05) (Figure 6C).
When rat brain sections were immunostained for 
ED1, a marker for activated microglia, and GFAP, a 
marker for activated astrocytes, a 44.5% reduction in the 
number of ED1+ cells (per 400 mm2) and a 26% reduction 
in GFAP+ area (as measured by optical density) were 
noted near the peri-infarct striatum in the UCB-PL group 
compared with the aged-PL group (Figure 6D). 
Taken together, our results indicate that UCB-
PL administration in the acute phase of an ischemic 
stroke model prevented or reversed behavioral and 
functional impairments more efficiently than aged-PL 
or PBS administration. Therefore, UCB-PL is a novel 
and promising cell-free therapeutic strategy for the safe 
allogeneic treatment of ischemic brain injury.
DISCUSSION
In this study, we successfully demonstrated 
that intravenous administration of UCB-PL improved 
behavioral performance post-MCAO in 3 behavioral 
tests, including the mNSS, the corner turn test, and the 
foot fault test. In support of the observed functional 
improvements, brain infarct size as measured by both MRI 
and Nissl staining was significantly reduced in the UCB-
PL group. Therefore, our results indicate that intravenous 
administration of UCB-PL in the acute phase after MCAO 
in rats improved behavioral performance and reduced 
structural damage.
UCB-PL is known to contain a variety of soluble 
factors, including growth factors, cytokines, and immune 
modulatory factors [16–20], that have the potential to 
ameliorate symptoms caused by ischemic stroke. UCB-PL, 
which does not contain any cells, has several advantages 
as a new therapeutic option; first, there is no risk of tumor 
formation or cell aggregation. In addition, UCB-PL is 
convenient to obtain, store, handle, and use (i.e., it can be 
frozen, thawed, transported, and administered to patients 
with ease) for clinical application. Furthermore, unlike 
bone marrow or peripheral blood, the absence of immune 
cells in UCB-PL signifies a decreased possibility of graft 
vs. host disease (GvHD) or immune rejection. 
At least possible 3 mechanisms for the efficacy of 
UCB-PL administration are supported by this study; (1) 
UCB-PL administration reduced neuroinflammation, as 
demonstrated by a reduced number of activated microglia 
in the peri-infarct area following UCB-PL administration; 
(2) UCB-PL administration increased neurogenesis in 
the SVZ area and, most likely, the migration of new cells 
to the injured area; and (3) soluble factors in UCB-PL 
had a paracrine effect on the injury site and caused the 
observed beneficial effects. Previous studies have reported 
that inflammation confers detrimental effects on neural 
proliferation in the injured brain [21, 22]. Therefore, 
increased neurogenesis by UCB-PL administration may be 
indirectly supported through the suppression of microglial 
activation and/or directly supported by the induction of 
neurogenesis by soluble factors in UCB-PL.
Intriguingly, plasma from a 65-year-old healthy 
subject did not produce the same beneficial effects as 
UCB-PL, suggesting that the composition of soluble 
factors in plasma from UCB and aged individuals are not 
only different but also have different degrees of therapeutic 
utility. Although beyond the scope of this study, it would 
be of interest to specifically identify the component(s) of 
UCB-PL that are responsible for the observed therapeutic 
effects (for example, by comparing the differences in the 
composition of the 2 different plasmas). 
MATERIALS AND METHODS
Animals
This section of the study was approved by the CHA 
University Institutional Animal Care and Use Committee. 
Middle cerebral artery occlusion (MCAO) was used 
to generate a rat model of ischemic stroke [23]. The 
surgery was conducted on adult male Sprague-Dawley 
rats (n = 30 per group) (Orient Bio, Seongnam, Korea) 
weighing 240–270 g each. Briefly, rats were anesthetized 
with 5% isoflurane (Hana Pharm, Hwasung, Korea) and 
were maintained under anesthesia with 2% isoflurane in 
a mixture of 70% N
2
 and 30% O
2
. The common carotid 
artery, internal carotid artery (ICA), and external carotid 
artery (ECA) were exposed by a cervical incision, and the 
pterygo-palatine and occipital arteries were cauterized. 
Blood flow was temporarily occluded by ligating the ICA 
and ECA. A 23-mm-long 4–0 nylon monofilament (Ailee, 
Busan, Korea) coated with low-viscosity silicone (Handae 
Chemicals, Chungbuk, Korea) was advanced from the 
exposed ECA to the ICA to occlude the middle cerebral 
artery. Reperfusion was induced by withdrawing the suture 
from the ECA at 1.5 h post-ischemia.
Preparation and administration of UCB-PL
This section of the study was approved by the 
Institutional Review Board of CHA Bundang Medical 
Center, Korea. Human UCB containing citrate phosphate 
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Figure 6: Comparison of therapeutic effects among the UCB-PL, aged-PL, and control groups. (A) Schedule of the 
experiment. (B) The behavioral performances of rats in each group were measured with using the modified neurologic severity score 
(mNSS) (left) and the beam balance test (right). (C) The percentage of damaged area per hemisphere was measured 3 weeks after the 
MCAO surgery. (D) The expression levels of ED1 and GFAP were measured in the peri-infarct striatum and compared among the 3 groups. 
The number of ED1-positive cells (right andupper graphs) and GFAP-positive optical density (right and lower graphs) were measured in 
the peri-infarct area. n = 5 for the control group, n = 6 for the aged-PL group, and n = 6 for the UCB-PL group. **p < 0.01, *p < 0.05; data 
are presented as the mean ± SEM. 
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dextrose adenine as an anticoagulant was obtained from 
the Cord Blood Bank, CHA Bundang Medical Center. 
Only fresh UCB supplied within 24 h postpartum was used 
in this study. For preparation, UCB was centrifuged for 
10 min at 1500 × g at room temperature and separated into 
3 layers; plasma (UCB-PL; top), a mixture of leucocytes 
and platelets (middle), and erythrocytes (bottom). The 
UCB-PL layer was carefully collected, aliquoted, and 
stored at −80°C until use. For comparison, plasma was also 
prepared from a 65-year-old healthy subject. The method 
of plasma preparation was the same as that described 
above. For administration, UCB-PL or control plasma 
(1 mL/kg) was intravenously injected slowly (1 to 2 min) 
into the tail vein according to the experimental schedules 
specified below. 
Behavioral tests 
The rats that showed similar behavioral defects 
were assigned randomly to each group. For behavioral 
assessments, each rat was subjected to a battery of 
behavioral tests and evaluated by an experimenter who 
was blinded to the treatment conditions. The modified 
neurologic severity score (mNSS), foot fault test, and 
beam balance test were performed on days −3, 0, 1, 3, 5, 
7, 14, and 21 post-MCAO surgery. The mNSS was used 
to assess motor (muscle status and abnormal movement), 
sensory (visual, tactile, and proprioceptive), and reflex 
(pinna, corneal, and startle) functions [24]. The test 
results were indexed as a grade that ranged from 0 to 18 
(0, no impairment; 1–6, mild impairment; 7–12, moderate 
impairment; and 13–18, severe impairment). 
The foot fault test was performed by placing rats on 
a wire grate (50 cm × 50 cm with 2.5 cm × 2.5 cm grids) 
for 5 minutes, and the number of times the forelimbs 
slipped through the grate during a 5-minute session was 
recorded (by videotaping from below the grate) [25]. Raw 
numbers were converted to foot fault scores as follows: 
Foot fault score = (number of faults for the affected 
forelimb/number of footsteps of the affected forelimb) − 
(number of faults for the unaffected forelimb/number of 
footsteps of the unaffected forelimb). 
The beam balance test was performed by placing 
rats at the center of a beam (100 cm × 5 cm × 2 cm) and 
grading motor performance on a 6-point scale, as follows 
[26]. 1, balances with steady posture and paws on top of 
the beam; 2, grasps the sides of the beam and has shaky 
movement; 3, one or more paw slips off of the beam; 4, 
attempts to balance on the beam but falls off; 5, drapes 
over the beam but falls off; and 6, falls off of the beam 
without attempting to balance.
5-Bromo-2-deoxyuridine (BrdU) labeling 
BrdU (50 mg/kg in saline) (Sigma-Aldrich, St. 
Louis, MO, USA) was administered intraperitoneally 
(i.p.) daily for 5 days starting the day after MCAO surgery. 
Rats were euthanized with a mixture of ketamine (50 
mg/kg, i.p.) (Huons, Seoul, Korea) and xylazine (5 mg/
kg, i.p.) (Bayer Korea, Seoul, Korea) and transcardially 
perfused with 0.1 M PBS followed by 4% formaldehyde 
(Samchun Chemicals, Pyeongtaek, Korea). Brains were 
removed and post-fixed in 4% formaldehyde overnight at 
4°C and then sequentially cryoprotected in 15% and 30% 
sucrose (Sigma-Aldrich) in phosphate-buffered saline. 
Brains were then stored at −80°C in an optimal cutting 
temperature (OCT) solution (Sakura Finetek, Torrance, 
CA, USA) and finally sectioned at a thickness of 30 μm 
using a cryostat (Microm, HM 525, Walldorf, Germany). 
To perform BrdU staining, brain sections were incubated 
in 2 N HCl (Samchun Chemicals) at 37°C for 30 min and 
subsequently neutralized in 0.1 M sodium borate (pH 8) 
(Sigma-Aldrich) for 20 min. Sections were then blocked 
with 10% goat serum (Vector Laboratories, Burlingame, 
CA, USA) and 0.1% NP-40 (Sigma-Aldrich) in Tris-
buffered saline (TBS) (Sigma-Aldrich) for 1 h, followed 
by incubation with 2 µg/mL of a rat monoclonal anti-BrdU 
antibody (Abcam) at 4°C for 12 h, and then with 2 µg/
mL of a goat Alexa 594-conjugated anti-rat IgG antibody 
(Invitrogen) for 40 min at room temperature. Sections 
were finally mounted on glass slides (Marienfeld, Lauda-
Koenig-Shofen, Germany) and examined with an LSM510 
or LSM610 confocal microscope (Carl Zeiss, Göttingen, 
Germany). 
Immunohistochemistry 
Immunostaining was performed as described 
above. The following primary antibodies were used: 
rabbit polyclonal anti-doublecortin (anti-DCX, 2 µg/
mL) (Cell Signaling Technology, Danvers, MA, USA), 
mouse anti-glial fibrillary acid protein (anti-GFAP, 
2 µg/ mL) (Millipore), mouse anti-neuronal nuclei (NeuN, 
2 µg/mL) (Millipore), rabbit polyclonal anti-ionized 
calcium-binding adapter molecule 1 (anti-Iba1, 2 µg/mL) 
(Wako Pure Chemical Industries, Osaka, Japan), and 
mouse monoclonal anti-macrophages/monocytes 
clone ED1 (anti-ED1/CD68, 2 µg/mL) (Millipore). 
The following secondary antibodies (4 µg/mL) were 
subsequently applied: goat Alexa 594-conjugated anti-
rat IgG, goat Alexa 594-conjugated anti-mouse IgG, goat 
Alexa 594-conjugated anti-mouse IgM, and goat Alexa 
594-conjugated anti-rabbit IgG (Invitrogen). Sections 
were examined with an LSM510 or LSM610 confocal 
microscope (Carl Zeiss). 
Measurement of infarction volume 
Three 30-μm coronal sections at the levels of 1.7 
mm, 0.7 mm, −0.3 mm, −1.3 mm, −2.3 mm, and −3.3 
mm from bregma were cut and mounted on glass slides 
(Marienfeld). The sections were stained with 0.2% cresyl 
violet (Sigma-Aldrich) and imaged using a dissecting 
microscope equipped with a digital camera (Olympus, 
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Tokyo, Japan). The size of the infarct area was measured 
using ImageJ v1.4 software (National Institutes of Health, 
Bethesda, MD, USA). Reductions in brain volume were 
calculated as follows: 
Brain volume reduction = (infarct size in the 
ipsilateral hemisphere)/(size of the intact contralateral 
hemisphere). 
Magnetic resonance imaging (MRI)
All MRI experiments were performed at the Korea 
Basic Science Institute in Ochang, Korea, using a 4.7-T 
animal MRI scanner (BioSpec 47/40; Bruker, Germany) 
with 72-mm rat brain surface coils for radiofrequency 
transmission and reception, respectively.
All axial rat brain images were obtained using 
a rapid acquisition with relaxation enhancement pulse 
sequence with the following parameters: repetition time = 
5 s, effective echo time = 90 ms, slice thickness = 1 mm, 
field of view = 3 × 4 cm2, matrix size = 256 × 256, number 
of averages = 4, and acquisition time = 10 min 40 s.
Statistical analysis
Behavioral scores were evaluated using a repeated-
measures ANOVA. Differences in the size of damaged 
brain areas between control and UCB-PL-treated groups 
were assessed using Student’s t-tests. Differences between 
control, UCB-PL-treated, and aged-PL-treated groups 
were assessed using a one-way ANOVA followed by 
Student-Newman-Keuls post hoc tests. Differences were 
considered statistically significant at p < 0.05. 
CONCLUSIONS
Overall, our study reveals, for the first time, 
the therapeutic efficacy of UCB-PL in a rat model of 
ischemic stroke. Furthermore, we have provided valuable 
information regarding the possible mechanisms underlying 
the efficacy of UCB-PL. Because of the therapeutic 
potential and inherent advantages of UCB-PL, this therapy 
is a promising option for the treatment of acute ischemic 
stroke patients who are not eligible for intravenous 
thrombolytic therapy.
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